New patents extend protection for Anaphylm™ into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe ...
The clinical trial data show that epinephrine delivered via orally administered Anaphylm™ (epinephrine) Sublingual Film is comparable to epinephrine delivered via autoinjector or manual intramuscular ...
Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world conditions, including heat, freezing, and water submersion New findings demonstrate dosing of ...
Anaphylm™ (epinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. Anaphylm is similar in size to a postage stamp, weighs less than an ounce, and begins to ...
Allergies have plagued over 100 million Americans, presenting a pervasive issue across the nation. Despite the widespread prevalence of allergies, the available treatment options are limited.
Aspire Biopharma (ASBP) announced top-line data from its recent randomized, crossover bioavailability trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of Aspire’s ...
Regulatory submission to expand the label for Igalmi use in the outpatient setting is expected in the first quarter of 2026. At-home administration of dexmedetomidine sublingual film as a treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback